Drug Overview
Portrazza (necitumumab; Eli Lilly) is a recombinant IgG1 monoclonal antibody (MAb) that blocks the binding of epidermal growth factor receptor (EGFR) to its ligands. This binding prevents downstream activity in parts of the EGFR pathway that are responsible for cellular proliferation, differentiation, and metastasis. The drug also has the potential to produce antibody-dependent cell-mediated cytotoxicity in cancer cells that express EGFR. Portrazza is a follow-up product to Erbitux (cetuximab; Eli Lilly/Merck KGaA), but unlike its predecessor it is a fully human MAb. Ideally, this allows Portrazza to have higher anti-tumor effects while presenting a lower risk for hypersensitivity.
Portrazza (necitumumab; Eli Lilly) is a recombinant IgG1 monoclonal antibody (MAb) that blocks the binding of epidermal growth factor receptor (EGFR) to its ligands. This binding prevents downstream activity in parts of the EGFR pathway that are responsible for cellular proliferation, differentiation, and metastasis. The drug also has the potential to produce antibody-dependent cell-mediated cytotoxicity in cancer cells that express EGFR. Portrazza is a follow-up product to Erbitux (cetuximab; Eli Lilly/Merck KGaA), but unlike its predecessor it is a fully human MAb. Ideally, this allows Portrazza to have higher anti-tumor effects while presenting a lower risk for hypersensitivity.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
